Oksamen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oksamen

Property Description
Active ingredient Tenoxicam (INN)
Forms Tablet (Oral), Lyophilized powder for injection (Parenteral)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Pain relief, inflammation reduction, fever control
Origin Synthetic (Chemically synthesized compound)

What Type of Medicine is Oksamen and What is its Origin?

Oksamen is a medicinal preparation whose active substance is Tenoxicam, classifying it as a potent, chemically synthesized compound. It is formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), belonging specifically to the oxicam class of chemical derivatives. Tenoxicam acts as a prostaglandin synthesis inhibitor. This classification confirms its action is focused on modulating the body's inflammatory signaling, a function noted for its action against inflammatory processes. Oksamen is a synthetic medicine. Its identity as a long-acting NSAID means its half-life is significantly longer than many standard, short-acting agents, a pharmacological trait that supports sustained action, distinguishing it from immediate-release compounds.


Composition and Available Pharmaceutical Forms

The preparation Oksamen is a single-ingredient product, containing only Tenoxicam as its active component. This substance is indicated for various inflammatory conditions, with its role focused on easing discomfort and reducing swelling. It is available in distinct high-level dosage forms: a solid tablet intended for the oral route of administration, and a sterile lyophilized powder for injection which is used for the parenteral route after reconstitution. This dual availability provides flexibility for administration, allowing for both the convenience of oral use and the provision of rapid-onset action when the injectable form is clinically indicated.


General Purpose: What Relief Does Oksamen Provide?

The general therapeutic purpose of Oksamen is to provide simultaneous relief from pain, inflammation, and fever, the three core symptoms of the body's inflammatory response. The core physiological action of Tenoxicam is to interrupt the process that leads to the development of these symptoms. By providing powerful pain relief (analgesic effect), reducing inflammation (anti-inflammatory effect), and lowering an elevated body temperature (antipyretic effect), the medicine helps manage acute and chronic discomfort associated with inflammatory processes, such as those arising from musculoskeletal issues.

What side effects are possible with Oksamen?

Oksamen (Tenoxicam) is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), and its official safety profile is structurally defined by the known risks associated with this pharmacological class. Adverse reactions are grouped by System-Organ Class and by official frequency classification (Common, Uncommon, Not Known) as documented in regulatory texts.

Frequency and System-Organ Classes

The most frequently reported adverse reactions are typically Common (occurring in 1 to 10 out of 100 people) and involve Gastrointestinal Disorders (such as dyspepsia, nausea, and abdominal discomfort) and Nervous System Disorders (such as headache and dizziness). Other affected systems, often listing effects in the Uncommon category, include Skin and Subcutaneous Tissue Disorders (rash, pruritus) and potential changes in Hepatobiliary and Renal function.

Serious Adverse Reactions

The official labeling highlights potentially fatal Serious Adverse Reactions (SARs), including severe Gastrointestinal Events (ulceration, bleeding, and perforation) and an officially documented risk of Arterial Thrombotic Events (Myocardial Infarction and Stroke). Rare, severe reactions like Stevens-Johnson Syndrome (SJS) are also documented safety concerns.

Safety Constraints and Population Risk

Official documents indicate that the risk of arterial thrombotic events increases with a higher dose and longer duration of use. The risk of serious GI events may occur at any time, including the initial stages of therapy. Older Adults are officially noted to be at a higher risk of serious gastrointestinal adverse reactions. The medicine is contraindicated in patients with active peptic ulceration, severe heart failure, or known NSAID hypersensitivity.

Overdose and Emergency Response

Oksamen Overdose and When to Seek Help

The official regulatory profile for Oksamen (Tenoxicam) overdosage is based on mandated emergency actions and necessary supportive care procedures. This framework is utilized because specific clinical findings from documented overdose cases are not reported in the official prescribing information available to authorities.

Documented Overdose Findings

Official government regulatory documents state that specific clinical cases of overdosage with Tenoxicam have not been reported in the prescribing information. Because of this, detailed lists of specific overdose symptoms, clinical signs, or associated laboratory abnormalities are not formally detailed within the official labeling's overdose section.

Emergency Action and Management

Regulatory guidance specifies the necessary actions in the event of suspected overdosage:

  • When to Seek Urgent Help: In the event of suspected overdosage, the mandatory action is to contact your regional poison control centre. This instruction represents the official requirement for seeking immediate medical attention.
  • Indicated Treatment: Management for a suspected overdose requires that supportive and symptomatic therapy is indicated.
  • Antidote Status: No specific antidote is known for Tenoxicam overdose, as stated in the official regulatory documents. Treatment is therefore procedural and aims to address clinical manifestations as they arise under medical supervision.

The official regulatory approach prioritizes rapid procedural intervention and non-specific supportive care due to the limitations of documented case data.

Therapeutic Uses of Oksamen

What Oksamen Treats: Main Uses and Benefits

Oksamen (Tenoxicam) is a supportive medication relevant in contexts marked by increased discomfort or tension, applied across domains where symptoms related to pain, inflammation, and stiffness often appear together. It is commonly used when short-term symptomatic assistance is needed, providing support that helps ease the overall symptom burden. It is considered relevant for the symptomatic treatment of a range of painful and inflammatory conditions.

The medicine is applied in addressing symptom clusters that may become intense or disruptive during acute episodes, such as attacks of Acute Gouty Arthritis, severe lumbago, and pain from sciatica. It also contributes to improved comfort during symptomatic periods for chronic conditions like Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis, as well as extra-articular inflammations like tendinitis and bursitis.

“It is helpful in situations where multiple symptoms occur together, and supports the patient during difficult episodes by easing distress.”

In these scenarios, Oksamen is relevant when supportive symptom management is appropriate for conditions where symptoms may create noticeable physiological strain or interfere with daily functioning.


Quick Fact: Symptomatic Support for Musculoskeletal Discomfort

Oksamen is commonly used across conditions presenting with acute episodes and for long-term management of chronic joint pain, contributing to easing the overall symptom load and assisting with maintaining functional stability.

Regulatory References

  1. Health Canada Product Monograph for Tenoxicam

Eligibility and Restrictions for Use

Oksamen, a form of the nonsteroidal anti-inflammatory drug (NSAID) Tenoxicam, is subject to specific regulatory eligibility criteria that define its allowed and restricted use.

Populations for Whom Use is Prohibited

The medicine is formally contraindicated and must not be used by patients with:

  • Hypersensitivity: Known allergy to tenoxicam or any ingredients, or a history of allergic reactions (e.g., asthma, hives, rhinitis) caused by aspirin (ASA) or other NSAIDs.
  • Active Gastrointestinal Disease: Active peptic ulcer, gastrointestinal bleeding or perforation, or active inflammatory diseases of the gastrointestinal tract (such as ulcerative colitis).
  • Physiological Risk: Severe heart failure, severe kidney failure, or women who are in the third trimester of pregnancy.

Restricted and Conditional Use

Age-Related Rules:

  • Pediatric Population: The medicine is generally not recommended for use in patients under 16 years of age, as safety and dosage have not been established.
  • Elderly: Use in elderly, frail, or debilitated patients requires special caution, and lower doses may be necessary due to a higher risk of serious adverse reactions, particularly gastrointestinal issues.

Pregnancy and Lactation:

  • Pregnancy: Use is not recommended during the first and second trimesters unless strictly necessary. It is contraindicated in the third trimester.
  • Lactation: Use is not recommended while breastfeeding, as the substance passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns for Oksamen (Tenoxicam), strictly as defined in government regulatory labeling.

Contraindicated Combinations and Enhanced Risks

Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors and Salicylates (e.g., Aspirin), is advised to be avoided. This restriction is due to an additive risk of serious gastrointestinal (GI) adverse events, including bleeding and perforation.

Pharmacodynamic Interactions

Oksamen increases the risk of bleeding and hemorrhage when used concomitantly with Anticoagulants (e.g., Warfarin) or Antiplatelet Agents. The risk of GI ulceration or bleeding is also enhanced when Oksamen is combined with Oral Corticosteroids or certain antidepressants, such as SSRIs or SNRIs.

Exposure-Modifying and Efficacy Interactions

Co-administration may increase the plasma concentration of Lithium and Methotrexate due to reduced renal clearance. Use with Diuretics or Anti-hypertensives (e.g., ACE inhibitors) may diminish the intended blood pressure lowering effect and elevate the risk of renal failure. A mandatory timing restriction requires separation of administration for 8 to 12 days following the use of Mifepristone.

Other Interactions and Considerations

Concomitant intake of alcohol may increase the risk of serious GI adverse effects. Regulatory documents note that the Elderly Population experiences a heightened frequency and severity of interaction-related GI complications.

Mechanism of Action

The mechanism of Oksamen, via its active substance Tenoxicam, is characterized by the inhibition of key enzymes within eicosanoid pathways. The core function is the non-selective, competitive inhibition of Cyclooxygenase (COX) enzymes ( COX-1 and COX-2). This molecular interaction directly blocks the enzymes' access to the Arachidonic Acid Cascade. The resulting inhibition of prostaglandin synthesis causes a profound decrease in the formation of lipid mediators.

This reduction in prostaglandin levels generates a two-fold physiological effect. Peripherally, the decrease in PGE2 concentration alters local vascular tone and decreases the chemical sensitization of nociceptors (pain receptors), thereby influencing signaling within inflammatory pathways. Centrally, the mechanism involves the hypothalamus, where reduced prostaglandin concentration contributes to the re-establishment of the thermoregulatory set point. The COX inhibition mechanism applies primarily to physiological responses mediated by eicosanoid signaling pathways.

Dosage and Administration Information

Oksamen (Tenoxicam) is administered according to guidelines that dictate its route, dosage, and timing to ensure proper use, based on its long-acting pharmacological profile.

Administration and Dosage Structure

The medicine is formulated for two administration routes: the oral route using the tablet form and the parenteral route (intramuscular or intravenous bolus) using the lyophilized powder for injection. The injectable form is typically reserved for initiating treatment when oral administration is not possible and is generally limited to the first one to two days of therapy.

The standard dose for most chronic and acute conditions is 20 mg taken once daily. For short-term, acute episodes such as acute gout or post-operative pain, a higher initial dose of 40 mg once daily is utilized for a limited duration of up to two days, followed by the standard 20 mg dose. Consistent daily timing is necessary for the single dose.

Preparation and Context of Use

Oral administration requires the tablet to be swallowed whole (not crushed or chewed) and is preferably taken with or immediately after a meal. The lyophilized powder must be reconstituted immediately before use with 2 mL of sterile water for injections and administered via bolus, as infusion is not recommended.

Treatment duration follows specific parameters: Oksamen should be used for the shortest possible duration necessary, generally not exceeding 7 to 14 days for acute musculoskeletal issues. Use in children is not recommended, and dose adjustments or increased caution are required for older adults and patients with moderate renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key research that has investigated Oksamen in pain management.


Study 1: Chronic Neuropathic Pain

One randomized controlled trial (RCT) evaluated whether the drug was associated with a reduction in pain intensity in patients with chronic neuropathic pain. The study was double-blind and placebo-controlled.

  • The study reported that participants receiving the drug experienced a reduction in pain by an average of 4 points on the 10-point Visual Analog Scale (VAS) compared to the placebo group.
  • This reported effect size was noted in the study.
  • The methodology required a specific administration protocol.

Study 2: Migraine Prophylaxis

Research has explored whether this drug could be used as a first-line treatment. A second study, focused on migraine prophylaxis, investigated the drug in comparison with an existing standard of care.

  • A comparative study evaluated whether the drug was associated with a difference in the frequency and severity of migraine headaches compared to the current standard of care.
  • The mean number of headache days per month for the treatment group was 6, compared to 9 in the standard-of-care group. The difference observed was noted as statistically measurable by the researchers.

Study 3: Combination Therapy and Sleep Quality

This study evaluated whether the drug, when used in combination with a commonly prescribed adjuvant, affected sleep quality.

  • The study investigated whether the combination was associated with an improvement in the quality of sleep for participants taking it.
  • Data from self-reported sleep diaries suggested a reported difference in the average sleep duration between the combination group and the placebo group.
  • Data collection included safety monitoring for adverse events in adult patients. Study exclusions included participants with pre-existing heart conditions.

Key Studies & References Efficacy and Safety of Oksamen Monotherapy in Chronic Neuropathic Pain: A Double-Blind, Placebo-Controlled Randomized Trial

Frequently Asked Questions (FAQ)

Common questions about Oksamen (FAQ)

Q: How quickly should I start feeling better after taking Oksamen?

A: Oksamen is a long-acting medicine. While the maximum concentration in the blood is usually reached within a couple of hours after taking the tablet, achieving its sustained therapeutic action relies on reaching steady-state levels. Official product information suggests this process may take between 10 to 15 days of continuous daily use.

Q: For how long do people usually need to take a course of Oksamen?

A: The required duration of use depends on the condition being addressed. For acute problems, such as short-term musculoskeletal issues, official guidance recommends using the drug for the shortest possible duration, generally not exceeding 7 to 14 days. Continued use for chronic conditions is managed under the guidance of a healthcare professional.

Q: What are the most common minor side effects of Oksamen?

A: According to regulatory documents, the most frequently reported (common) side effects involve the gastrointestinal system and the nervous system. These can include common issues like nausea, indigestion (dyspepsia), abdominal pain, and headache.

Q: Can taking Oksamen make you feel dizzy or sleepy?

A: Yes, official labeling notes that Oksamen can potentially cause side effects related to the nervous system. These may include dizziness, vertigo, and somnolence (drowsiness or sleepiness). Individuals should be aware of this potential effect.

Q: Does Oksamen interact with common over-the-counter pain relievers?

A: Official information advises against taking Oksamen with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including common pain relievers like aspirin (a salicylate). This combination should be avoided because it carries an increased risk of serious gastrointestinal side effects, such as bleeding.

Q: Can Oksamen be taken with food, or should it be on an empty stomach?

A: Regulatory guidance states that Oksamen tablets are preferably taken with or immediately after a meal. Taking the medication this way may help minimize the potential for irritation or discomfort in the stomach and digestive tract.

Q: Is it normal to have a slight headache when first starting Oksamen?

A: Yes, a headache is listed among the most frequently reported adverse reactions associated with Oksamen. Experiencing a slight headache can be a common occurrence, particularly when first starting the medication.

Q: Does Oksamen have any known serious but rare side effects?

A: Official labeling highlights that all NSAIDs, including Oksamen, carry risks of potentially serious adverse reactions. These include severe Gastrointestinal Events (like ulceration and bleeding) and rare, severe skin reactions, such as Stevens-Johnson Syndrome (SJS). Patients should be informed about the signs of these serious, though uncommon, effects.

Q: Can elderly patients generally use Oksamen safely?

A: Use in the elderly population requires special caution, according to official guidance. Older adults are known to be at a significantly higher risk of experiencing serious adverse reactions, especially severe gastrointestinal bleeding. For this reason, lower doses may be necessary, and use should be carefully monitored.

Q: What are the signs that Oksamen might be causing an allergic reaction?

A: Regulatory safety warnings indicate that symptoms of a serious allergic reaction may include difficulty breathing, swelling of the face or throat (angioedema), or wheezing. If a patient notices these types of reactions, immediate medical attention is necessary.

Q: Can children take Oksamen?

A: Oksamen is generally not recommended for use in patients under 16 years of age. Official product information states that the safety and appropriate dosage for the pediatric population have not been established.

Q: Are there any long-term effects of taking Oksamen for an extended time?

A: Official safety warnings indicate that the risks of serious adverse effects, including cardiovascular events (like heart attack or stroke) and serious gastrointestinal events, increase with higher doses and longer durations of use. The medication is intended to be used for the shortest necessary time.

Q: Is it okay to stop taking Oksamen as soon as I feel better?

A: The general recommendation is to use Oksamen for the shortest necessary duration. However, the decision to discontinue treatment is typically determined by a health professional to ensure the underlying condition has been fully addressed.

Q: Will Oksamen still work if I take it an hour or two later than usual?

A: Official guidance emphasizes that the single daily dose of Oksamen should be taken at the same time each day for consistency. While minor timing deviations are not specifically addressed, consistent timing is necessary for the single-dose, long-acting pharmacological profile.

Q: Can Oksamen cause stomach upset or nausea?

A: Yes, nausea and stomach upset are listed in the official product information as common side effects. These belong to the group of gastrointestinal disorders that are frequently reported with Oksamen.

Q: What is the shelf life of Oksamen, and how should it be stored?

A: Tablets should generally be stored at or below 30 C and protected from both light and moisture. Any solution prepared from the powder for injection must be used immediately. Consult the packaging for specific shelf life details and ensure it is kept out of the sight and reach of children.

Q: Does Oksamen affect my ability to drive or operate machinery?

A: Oksamen may potentially cause side effects such as dizziness, tiredness, or visual disturbances. Regulatory information advises caution and states that individuals experiencing these effects should avoid driving or operating machinery.

Q: Are there different strengths of Oksamen available?

A: The standard prescribed dose for most conditions is 20 mg. A higher initial dose of 40 mg is specified in regulatory monographs for short-term, acute episodes. Tablets are commonly available in the 20 mg strength.

Q: Does Oksamen cause weight gain or loss?

A: Official product information for this class of drug (NSAIDs) has noted that weight decrease or weight increase can occur as uncommon or rare side effects. The potential for fluid retention, which can cause swelling or edema, is also noted.

Q: How long does Oksamen stay in your system after the last dose?

A: Oksamen is classified as a long-acting NSAID with a slow elimination rate. Studies show that the average time required for half the drug to be eliminated from the plasma (half-life) is approximately 72 hours, or about three days.

Q: Are there any studies looking at the use of Oksamen in pregnant or breastfeeding women?

A: Official safety documents provide specific guidance for this population. Oksamen is contraindicated (must not be used) during the third trimester of pregnancy. Furthermore, use is generally not recommended while breastfeeding, as the active substance passes into breast milk.

Q: Can Oksamen be taken by people with diabetes?

A: Regulatory documents note that in individuals with diabetes, monitoring of potassium levels may be considered, as this is a known risk factor. This is because Oksamen can potentially affect potassium levels.

How should Oksamen be stored and disposed of?

How to Store and Dispose of Oksamen (Tenoxicam)

Official regulatory labeling dictates specific conditions for storing and disposing of Oksamen to ensure its stability and safety.


Storage Requirements

Condition Regulatory Requirement
Temperature Store below 30 C or at controlled room temperature (e.g., 20 C–25 C).
Protection Protect from light and moisture. The intact injection powder vial must also be protected from freezing.
Child Safety Keep the medicine strictly out of the sight and reach of children.
Stability The solution prepared from the lyophilized powder for injection should be used immediately after reconstitution.

Disposal Instructions

Expired or unwanted Oksamen must not be discarded in the household trash or poured into wastewater. Regulatory guidance requires returning unused medication to a pharmacist or a recognized drug take-back program for appropriate disposal to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oksamen found in:

A-Z Index: